Strata Critical Medical, Inc. (SRTA) SEC Filings & Earnings Calls
EquiReason read 21 Strata Critical Medical, Inc. SEC filings in the last 12 months. Latest: SC 13D on 2026-10-15 — Schedule 13D: Third Point LLC 5.8%.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 20268-K · 2.02Revenue $73M (+61% y/y); Adjusted EBITDA $8M (+220% y/y); Net loss from continuing operations $-11Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $73M | +61% y/y |
| Adjusted EBITDA · Q2-2026 | $8M | +220% y/y |
| Net loss from continuing operations · Q2-2026 | $-11M | |
| Free Cash Flow · Q2-2026 | $3M | |
| Cash flow from operating activities · Q2-2026 | $6M | |
| Logistics Revenue · Logistics · Q2-2026 | $48M | +7% y/y |
| Clinical Revenue · Clinical · Q2-2026 | $24M | |
| Gross margin · Q2-2026 | 21.0% |
Risks flagged
Net loss from continuing operations widened significantly due to amortization and acquisition costs.
“Net loss from continuing operations $(10.5) million vs $(3.4) million prior year; amortization of intangible assets $6.6 million vs $0.4 million.” · word for word
Logistics gross margin declined 160 bps YoY, indicating cost pressure in that segment.
“Logistics gross margin 18.4% vs 20.0% prior year.”
4 Aug 202610-QStrata Critical Medical reported Q2 2026 results with strong revenue growth driven by acquisitions, but continued net losses and declining liquidity.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $73M | +61% y/y |
| Logistics revenue · Logistics · Q2-2026 | $48M | +7% y/y |
| Clinical revenue · Clinical · Q2-2026 | $24M | |
| Gross profit · Q2-2026 | $15M | +69% y/y |
| Gross margin · Q2-2026 | 21.0% | |
| Net loss from continuing operations · Q2-2026 | $-11M | +209% y/y |
| Adjusted EBITDA · Q2-2026 | $8M | +220% y/y |
| Cash and cash equivalents · 2026-06-30 | $16M |
Risks flagged
Dependence on organ supply
“The majority of our business is directly tied to the volume of heart, liver, and lung transplants performed in the United States, which is driven primarily by the supply of donor organs that become available.” · word for word
Fuel cost volatility
“The decrease in gross margin is mostly attributable to: (i) higher fuel surcharge and fuel costs” · word for word
Integration risk from acquisitions
“our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestiture of the Passenger business, the acquisition and integration of Keystone” · word for word
Liquidity risk
“As of June 30, 2026 and December 31, 2025, we had total liquidity of $22.8 million and $61.2 million, respectively” · word for word
8 May 2026SC 13D/AThe reporting person's warrants expired worthless, reducing their beneficial ownership to 0% and ceasing to be a 5% holder.open
Risks flagged
Warrant Expiration Risk
“The 1,577,500 Warrants previously held by the Reporting Person (SRTAW) expired worthless on May 7, 2026.” · word for word
8 May 2026SC 13D/AThe reporting person's warrants expired worthless, reducing their beneficial ownership to 0% and ceasing to be a 5% holder.open
Risks flagged
Warrant Expiration Risk
“The 1,577,500 Warrants previously held by the Reporting Person (SRTAW) expired worthless on May 7, 2026.” · word for word
6 May 20268-K · 2.02Total Revenue $67M (+87% y/y); Logistics Revenue $48M (+32% y/y); Clinical Revenue $20Mearningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $67M | +87% y/y |
| Logistics Revenue · Logistics · Q1-2026 | $48M | +32% y/y |
| Clinical Revenue · Clinical · Q1-2026 | $20M | |
| Total Gross Profit · Q1-2026 | $14M | +100% y/y |
| Net Income from Continuing Operations · Q1-2026 | $2M | |
| Adjusted EBITDA · Q1-2026 | $6M | +1441% y/y |
| Clinical Gross Profit · Clinical · Q1-2026 | $5M |
Guidance
Company reiterated full year 2026 guidance, reflecting confidence in growth trajectory.
Risks flagged
Winter storms impacted logistics operations; customer mix led to shorter trip distances.
“This was partially offset by customer mix, that drove shorter trip distances, and winter storms that resulted in the closure of key airports for several days during the quarter.” · word for word
6 May 202610-QTotal revenue $67M (+87% y/y); Logistics revenue $48M (+32% y/y); Clinical revenue $20Mopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $67M | +87% y/y |
| Logistics revenue · Logistics · Q1-2026 | $48M | +32% y/y |
| Clinical revenue · Clinical · Q1-2026 | $20M | |
| Gross profit · Q1-2026 | $14M | +100% y/y |
| Gross margin · Q1-2026 | 21.0% | |
| Net income (loss) from continuing operations · Q1-2026 | $2M | |
| Adjusted EBITDA · Q1-2026 | $6M | +1441% y/y |
| Cash and cash equivalents · 2026-03-31 | $59M | |
| Short-term investments · 2026-03-31 | $100000.00 | |
| Total liquidity · 2026-03-31 | $59M |
Risks flagged
Dependence on organ donor supply
“The majority of our business is directly tied to the volume of heart, liver, and lung transplants performed in the United States, which is driven primarily by the supply of donor organs that become available.” · word for word
Integration risk from Keystone acquisition
“Our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestiture of the Passenger business, the acquisition and integration of Keystone.” · word for word
Competition from organ preservation equipment manufacturers
“Increasingly, we compete directly with manufacturers of organ preservation equipment that also offer transportation or with providers that offer additional services.” · word for word
16 Apr 2026SC 13D/AActivist investor Velibor Krstic increased warrant position to 16.21% and is publicly demanding a mandatory exchange to prevent warrants from expiring worthless on May 7, 2026.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $14M | |
| Cash and Equivalents · 2026-04-15 | $61M |
Guidance
2026 Adjusted EBITDA target raised to $29-33M from prior (not stated), representing >30% annualized growth
Management raised 2026 Adjusted EBITDA guidance to $29-33M, citing record 2025 results and strong liquidity.
Risks flagged
Warrant Expiration Risk
“The Reporting Person believes that a Mandatory Exchange via Amendment is the only rational solution to stabilize the capital structure before the May 7 2026 expiration.” · word for word
Governance / Fiduciary Duty Dispute
“the inaction of the Board would be interpreted as a premeditated destruction of value and a breach of fiduciary duty.” · word for word
16 Apr 2026SC 13D/AActivist investor Velibor Krstic increased warrant position to 16.21% and is publicly demanding a mandatory exchange to prevent warrants from expiring worthless on May 7, 2026.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $14M | |
| Cash and Equivalents · 2026-04-15 | $61M |
Guidance
2026 Adjusted EBITDA target raised to $29-33M from prior (not stated), representing >30% annualized growth
Management raised 2026 Adjusted EBITDA guidance to $29-33M, citing record 2025 results and strong liquidity.
Risks flagged
Warrant Expiration Risk
“The Reporting Person believes that a Mandatory Exchange via Amendment is the only rational solution to stabilize the capital structure before the May 7 2026 expiration.” · word for word
Governance / Fiduciary Duty Dispute
“the inaction of the Board would be interpreted as a premeditated destruction of value and a breach of fiduciary duty.” · word for word
14 Apr 2026DEF 14ADEF 14A proxy statement detailing executive compensation, governance changes, and business transformation following sale of passenger segment and acquisition of Keystone.open
Figures in the filing · each found in the filing text
| Net Income from Continuing and Discontinued Operations · FY2025 | $41M | |
| Adjusted EBITDA · FY2025 | $15M | |
| Medical Adjusted EBITDA · Clinical · FY2025 | $24M | |
| European Adjusted EBITDA · Logistics · FY2025 | $1M | |
| Medical Net Income · Clinical · FY2025 | $17M | |
| European Net Income · Logistics · FY2025 | $670000.00 |
Risks flagged
Integration risk from Keystone acquisition
“The purchase price has been adjusted downward by approximately $3.3 million based on Keystone's 2025 adjusted EBITDA performance.” · word for word
Dependence on organ transplant ecosystem
“Strata's goals are closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, OPOs and other service providers.” · word for word
Concentration of ownership and governance risk
“Steele ExpCo Holdings, LLC beneficially owns 13.7% of outstanding common stock and has director nomination rights under the Investor Rights Agreement.”
8 Apr 2026SC 13D/AInvestor Krstic disclosed 12.4% warrant stake and intent to engage management on value-maximizing actions before May 2026 expiry.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA | $14M |
8 Apr 2026SC 13D/AInvestor Krstic disclosed 12.4% warrant stake and intent to engage management on value-maximizing actions before May 2026 expiry.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA | $14M |
7 Apr 2026SC 13DInvestor acquires 8.3% warrant stake in Strata Critical Medical and intends to engage with management and sponsor to maximize value, citing $14.1M Adjusted EBITDA.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $14M | |
| Warrant Ownership · 2026-04-01 | 8.3% |
Risks flagged
Warrant Expiration Risk
“The Reporting Person intends to actively monitor the decisions of the Board of Directors and management leading up to the Warrant expiration date of May 7, 2026.” · word for word
7 Apr 2026SC 13DInvestor acquires 8.3% warrant stake in Strata Critical Medical and intends to engage with management and sponsor to maximize value, citing $14.1M Adjusted EBITDA.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $14M | |
| Warrant Ownership · 2026-04-01 | 8.3% |
Risks flagged
Warrant Expiration Risk
“The Reporting Person intends to actively monitor the decisions of the Board of Directors and management leading up to the Warrant expiration date of May 7, 2026.” · word for word
3 Mar 202610-KRevenue $197M (+34% y/y); Gross Margin 21; Adjusted EBITDA $14M (+274% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $197M | +34% y/y |
| Gross Margin · FY2025 | 21.0% | |
| Adjusted EBITDA · FY2025 | $14M | +274% y/y |
| Logistics Revenue · Logistics · FY2025 | $177M | +20% y/y |
| Clinical Revenue · Clinical · FY2025 | $20M | |
| Net Income (Loss) · FY2025 | $41M | |
| Cash and Cash Equivalents · 2025-12-31 | $31M | +93% y/y |
| Short-term Investments · 2025-12-31 | $30M | -72% y/y |
Risks flagged
Donor Supply Flattening
“recent months have shown a flattening in the number of deceased organ donors in America.” · word for word
Clinician Inflation
“Given significant growth in organ transplant volumes and an increasing percentage of organs that are recovered by commercial surgeons and undergo NRP, demand for clinicians skilled in these procedures is high resulting in inflation in salaries and fees paid to these practitioners.” · word for word
Aircraft Capacity Availability
“Periods of increased demand for private jets have historically led to increased charter costs and more limited availability in the spot jet charter market.” · word for word
3 Mar 20268-K · 2.02Revenue $67M (+84% y/y); Revenue $197M (+34% y/y); Adjusted EBITDA $14M (+274% y/y); Guidance: FY2026 revenue $260-275M, Adj. EBITDA $29-33Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $67M | +84% y/y |
| Revenue · FY2025 | $197M | +34% y/y |
| Adjusted EBITDA · FY2025 | $14M | +275% y/y |
| Net loss from continuing operations · FY2025 | $-20M | +24% y/y |
| Logistics revenue · Logistics · Q4-2025 | $49M | +35% y/y |
| Clinical revenue · Clinical · Q4-2025 | $18M |
Guidance
FY2026 revenue $260-275M, Adj. EBITDA $29-33M
Raising FY2026 guidance above prior expectations; strong organic growth and M&A pipeline.
Risks flagged
Net loss from continuing operations increased 24.2% Y/Y; operating expenses growing faster than gross profit.
“Net loss from continuing operations $20.1 million in FY2025 vs $16.2 million in FY2024.”
5 Feb 20268-K · 1.01, 7.01Strata Critical Medical entered a $30M ABL revolving credit facility (expandable to $50M) to support acquisition strategy; undrawn at close.open
Figures in the filing · each found in the filing text
| ABL facility size | $30M | |
| ABL facility maximum | $50M |
10 Nov 20258-K · 2.02Revenue $49M (+37% y/y); Net loss from continuing operations $-10M (+72% y/y); Gross margin 19.4; Guidance: Revenue guidance raised to $185-195 million from prior rangeearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $49M | +37% y/y |
| Net loss from continuing operations · Q3-2025 | $-10M | +72% y/y |
| Gross margin · Q3-2025 | 19.4% | |
| Flight Profit · Flight · Q3-2025 | $12M | +55% y/y |
| Flight Margin · Flight · Q3-2025 | 23.6% | |
| Adjusted EBITDA · Q3-2025 | $4M | +6190% y/y |
| Cost of revenue · Q3-2025 | $38M | +32% y/y |
Guidance
Revenue guidance raised to $185-195 million from prior range
Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range; organic growth accelerated to 29.0% in Q3; Medical Segment Adjusted EBITDA margin expanded 450 bps.
Risks flagged
Net loss increased significantly due to realized losses on short-term investments and legal reserve.
“Net Loss from continuing operations increased by $4.0 million versus the prior year to $(9.7) million driven primarily by a $5.2 million increase in realized loss from sales of short-term investments and a legal reserve” · word for word
Integration risk from Keystone acquisition; potential for execution missteps.
“Our integration of Keystone is off to a fantastic start” · word for word
10 Nov 202510-QReported strong revenue growth (+36.7% QoQ), margin expansion (Flight Margin +280bps), and significant gain from sale of Passenger business.earningsopen
Figures in the filing · each found in the filing text
| Revenue · continuing operations · Q3-2025 | $49M | +37% y/y |
| Revenue · continuing operations · 9M-2025 | $130M | +18% y/y |
| Net loss from continuing operations · continuing operations · Q3-2025 | $-10M | |
| Net loss from continuing operations · continuing operations · 9M-2025 | $-15M | |
| Adjusted EBITDA · continuing operations · Q3-2025 | $4M | +6190% y/y |
| Adjusted EBITDA · continuing operations · 9M-2025 | $7M | +165% y/y |
| Flight Profit · continuing operations · Q3-2025 | $12M | +55% y/y |
| Flight Margin · continuing operations · Q3-2025 | 23.6% | |
| Gross Margin · continuing operations · Q3-2025 | 19.4% | |
| Cash and cash equivalents · 2025-09-30 | $23M |
Risks flagged
Organ supply volatility
“However, there is no guarantee that this growth will continue, for example, recent months have shown decreased availability of donor organs.” · word for word
Legal costs from Drulias lawsuit
“Legal expenses and advocacy fees provisions related to the Drulias lawsuit ... $5,045 thousand for the three months ended September 30, 2025.” · word for word
Integration risk from Keystone acquisition
“Our ability to successfully integrate Keystone and to identify, complete and successfully integrate future acquisitions.” · word for word
Strata Critical Medical, Inc. — questions
- What did Strata Critical Medical, Inc. file recently?
- 21 SEC filings in the last 12 months. Latest: SC 13D on 2026-10-15 — Schedule 13D: Third Point LLC 5.8%
Every figure on this page comes from Strata Critical Medical, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.